Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.
This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Reject Nonessential Cookies Accept All Cookies
Skip to main content
Click to go back to the Pipeline page Back To Explore Our Pipeline

Disable motion

XB010:
5T4-MMAE
ADC

XB010 is a monomethyl auristatin E (MMAE) ADC and the first custom ADC generated through Exelixis’ biotherapeutics collaboration network.
Molecular structure shown is an artistic rendering.
XB010 is an ADC shown in human xenograft models to target the tumor antigen 5T4, which is overexpressed in many solid tumors.
Phase 1 dose-escalation and expansion study of XB010 alone and in combination in locally advanced or metastatic solid tumors.
Cohort Expansions
For more information, visit
clinicaltrials.gov/study/NCT06545331
This website includes information on investigational uses of compounds that have not been approved by the U.S. Food and Drug Administration (FDA). Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.
Explore All
Pipeline Clinical Trials
Click to go to Resource